Novus Therapeutics Inc

Novus Therapeutics Inc (NVUS)

$0.8922
0.0016 (+0.18%)
Buy
Symbol NVUS
Price 0.8,922$
Beta 2.521
Volume Avrg. 3.70M
Market Cap 0.02B
Shares (2019) 11,799.47K
Last Div 0
Dividend Yield -
DCF Unlevered -
DCF Levered -
ROE -169.16% Strong Sell
ROA -146.47% Strong Sell
Operating Margin -Infinity% Strong Sell
Debt / Equity 15.49% Neutral
P/E -0.48 Neutral
P/B 0.81 Buy

Retained Earning Schedule

Year 2012 2013 2014 2015 2016 2017 2018 2019
Retained Earnings (Previous Year) --47-63-86-131-169-28-42
Net Income -10-16-23-45-38-13-14-16
Stock Dividends -38-00--155--
Dividend Paid --------
Retained Earnings -47-63-86-131-169-28-42-58

PPE Schedule

Year 2012 2013 2014 2015 2016 2017 2018 2019
Gross PPE ---00000
Annual Depreciation 0001-0-0-00
Capital Expenditure -0-0--1-0---
Net PPE --000000

Intangible and Goodwill Schedule

Year 2012 2013 2014 2015 2016 2017 2018 2019
Intangible and Goodwill (Previous Year) ------22
New Purchases ----40-1---
Intangible and Goodwill -----22-

About


Mr. Gregory Flesher
Healthcare
Biotechnology
NASDAQ Capital Market

Novus Therapeutics Inc. engages in the research and development of pharmaceutical products for patients with disorders of the ear, nose, and throat. The company is headquartered in Irvine, California and currently employs 10 full-time employees. The firm is focused on the acquisition, development, and commercialization of ear, nose, and throat products. The company has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction. OP-02 is a combination drug product, which comprises two components: surfactant dipalmitoylphosphatidylcholine and a spreading agent cholesteryl palmitate. The product is sprayed through the nostrils toward the opening of the Eustachian tube at the back of the nasal cavity.